{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:06:17Z","timestamp":1792724777718,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["Grant Nr. 310030B_163479\/1"],"award-info":[{"award-number":["Grant Nr. 310030B_163479\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"EC | European Research Council","doi-asserted-by":"publisher","award":["670603 \u201cZAUBERKUGEL\u201d"],"award-info":[{"award-number":["670603 \u201cZAUBERKUGEL\u201d"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"EC | European Research Council","doi-asserted-by":"publisher","award":["CoG-648455"],"award-info":[{"award-number":["CoG-648455"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1038\/s41375-019-0434-8","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T16:04:10Z","timestamp":1552061050000},"page":"2155-2168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["A fully human anti-IL-7R\u03b1 antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"33","author":[{"given":"Padma","family":"Akkapeddi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Fragoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Hixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Sofia","family":"Ramalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana L.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Gloger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Matasci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Corzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Durum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gon\u00e7alo J. L.","family":"Bernardes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o T.","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"key":"434_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nrd2240","volume":"6","author":"CH Pui","year":"2007","unstructured":"Pui C-H, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007;6:149\u201365.","journal-title":"Nat Rev Drug Discov"},{"key":"434_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/3877","volume":"20","author":"A Puel","year":"1998","unstructured":"Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T-B\u2009+\u2009NK\u2009+\u2009severe combined immunodeficiency. Nat Genet. 1998;20:394\u20137.","journal-title":"Nat Genet"},{"key":"434_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/1074-7613(95)90047-0","volume":"2","author":"X Cao","year":"1995","unstructured":"Cao X, Shores EW, Hu-Li J, Anver MR, Kelsail BL, Russell SM, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor \u03b3 chain. Immunity. 1995;2:223\u201338.","journal-title":"Immunity"},{"key":"434_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1084\/jem.177.2.305","volume":"177","author":"BE Rich","year":"1993","unstructured":"Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med. 1993;177:305\u201316.","journal-title":"J Exp Med"},{"key":"434_CR5","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1038\/sj.onc.1208726","volume":"24","author":"N Abraham","year":"2005","unstructured":"Abraham N, Ma MC, Snow JW, Miners MJ, Herndier BG, Goldsmith MA. Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas. Oncogene. 2005;24:5252\u20137.","journal-title":"Oncogene"},{"key":"434_CR6","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/0008-5472.CAN-10-3606","volume":"71","author":"A Silva","year":"2011","unstructured":"Silva A, Laranjeira ABA, Martins LR, Cardoso BA, Demengeot J, Andr\u00e9s Yunes J, et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res. 2011;71:4780\u20139.","journal-title":"Cancer Res"},{"key":"434_CR7","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2003-06-2126","volume":"103","author":"Y Laouar","year":"2004","unstructured":"Laouar Y, Crispe IN, Flavell RA. Overexpression of IL-7Ra provides a competitive advantage during early T-cell development. Blood. 2004;103:1985\u201394.","journal-title":"Blood"},{"key":"434_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3324\/haematol.10356","volume":"92","author":"MT Scupoli","year":"2007","unstructured":"Scupoli MT, Perbellini O, Krampera M, Vinante F, Cioffi F, Pizzolo G. Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. Haematologica. 2007;92:264\u20136.","journal-title":"Haematologica"},{"key":"434_CR9","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood.V75.11.2097.2097","volume":"75","author":"I Touw","year":"1990","unstructured":"Touw I, Pouwels K, van Agthoven T, van Gurp R, Budel L, Hoogerbrugge H, et al. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood. 1990;75:2097\u2013101.","journal-title":"Blood"},{"key":"434_CR10","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/ng.924","volume":"43","author":"PP Zenatti","year":"2011","unstructured":"Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011;43:932\u20139.","journal-title":"Nat Genet"},{"key":"434_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.3","volume":"7","author":"P Richter-Pecha\u0144ska","year":"2017","unstructured":"Richter-Pecha\u0144ska P, Kunz JB, Hof J, Zimmermann M, Rausch T, Bandapalli OR, et al. Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. Blood Cancer J. 2017;7:e523.","journal-title":"Blood Cancer J"},{"key":"434_CR12","first-page":"1459","volume":"89","author":"JT Barata","year":"2004","unstructured":"Barata JT, Keenan TD, Silva A, Nadler LM, Boussiotis VA, Cardoso AA. Common \u03b3 chain-signaling cytokines promote proliferation of T-cell lymphoblastic leukemia. Haematologica. 2004;89:1459\u201367.","journal-title":"Haematologica"},{"key":"434_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1084\/jem.20040789","volume":"200","author":"JT Barata","year":"2004","unstructured":"Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med. 2004;200:659\u201369.","journal-title":"J Exp Med"},{"key":"434_CR14","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/leu.2016.83","volume":"30","author":"K Cant\u00e9-Barrett","year":"2016","unstructured":"Cant\u00e9-Barrett K, Spijkers-Hagelstein JAP, Buijs-Gladdines JGCAM, Uitdehaag JCM, Smits WK, Van Der Zwet J, et al. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia. 2016;30:1832\u201343.","journal-title":"Leukemia"},{"key":"434_CR15","doi-asserted-by":"publisher","first-page":"15113","DOI":"10.1073\/pnas.2436348100","volume":"100","author":"VI Brown","year":"2003","unstructured":"Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA. 2003;100:15113\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"434_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s002770050495","volume":"78","author":"AEJ Duyn","year":"1999","unstructured":"Duyn AEJ, Kaspers GJL, Pieters R, Van Zantwijk CH, Broekema GJ, H\u00e4hlen K, et al. Effects of interleukin 3, interleukin 7, and B-cell growth factor on proliferation and drug resistance in vitro in childhood acute lymphoblastic leukemia. Ann Hematol. 1999;78:163\u201371.","journal-title":"Ann Hematol"},{"key":"434_CR17","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1182\/blood.V99.11.4109","volume":"99","author":"C Wuchter","year":"2002","unstructured":"Wuchter C, Ruppert V, Schrappe M, D\u00f6rken B, Ludwig WD, Karawajew L. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood. 2002;99:4109\u201315.","journal-title":"Blood"},{"key":"434_CR18","doi-asserted-by":"publisher","first-page":"e1002200","DOI":"10.1371\/journal.pmed.1002200","volume":"13","author":"Y Li","year":"2016","unstructured":"Li Y, Buijs-Gladdines JGCAM, Cant\u00e9-Barrett K, Stubbs AP, Vroegindeweij EM, Smits WK, et al. IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study. PLoS Med. 2016;13:e1002200.","journal-title":"PLoS Med"},{"key":"434_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc3930","volume":"15","author":"GJ Weiner","year":"2015","unstructured":"Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15:361\u201370.","journal-title":"Nat Rev Cancer"},{"key":"434_CR20","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/nbt.3040","volume":"32","author":"G Walsh","year":"2014","unstructured":"Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol. 2014;32:992\u20131000.","journal-title":"Nat Biotechnol"},{"key":"434_CR21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.tips.2016.09.005","volume":"37","author":"BV Ayyar","year":"2016","unstructured":"Ayyar BV, Arora S, O\u2019Kennedy R. Coming-of-age of antibodies in cancer therapeutics. Trends Pharmacol Sci. 2016;37:1009\u201328.","journal-title":"Trends Pharmacol Sci"},{"key":"434_CR22","doi-asserted-by":"publisher","first-page":"e100000","DOI":"10.1371\/journal.pone.0100000","volume":"9","author":"M Weber","year":"2014","unstructured":"Weber M, Bujak E, Putelli A, Villa A, Matasci M, Gualandi L, et al. A highly functional synthetic phage display library containing over 40 billion human antibody clones. PLoS ONE. 2014;9:e100000.","journal-title":"PLoS ONE"},{"key":"434_CR23","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1002\/pmic.200401273","volume":"5","author":"M Silacci","year":"2005","unstructured":"Silacci M, Brack S, Schirru G, M\u00e5rlind J, Ettorre A, Merlo A, et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics. 2005;5:2340\u201350.","journal-title":"Proteomics"},{"key":"434_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.4161\/mabs.22271","volume":"4","author":"T List","year":"2012","unstructured":"List T, Neri D. Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. Mabs. 2012;4:775\u201383.","journal-title":"Mabs"},{"key":"434_CR25","doi-asserted-by":"publisher","first-page":"13128","DOI":"10.1038\/ncomms13128","volume":"7","author":"B Bernardim","year":"2016","unstructured":"Bernardim B, Cal PMSD, Matos MJ, Oliveira BL, Mart\u00ednez-Sa\u00e9z N, Albuquerque IS, et al. Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents. Nat Commun. 2016;7:13128\u201337.","journal-title":"Nat Commun"},{"key":"434_CR26","doi-asserted-by":"publisher","first-page":"D313","DOI":"10.1093\/nar\/gkw1132","volume":"45","author":"S Bienert","year":"2017","unstructured":"Bienert S, Waterhouse A, De Beer TAP, Tauriello G, Studer G, Bordoli L, et al. The SWISS-MODEL repository-new features and functionality. Nucleic Acids Res. 2017;45:D313\u20139.","journal-title":"Nucleic Acids Res"},{"key":"434_CR27","doi-asserted-by":"publisher","first-page":"W363","DOI":"10.1093\/nar\/gki481","volume":"33","author":"D Schneidman-Duhovny","year":"2005","unstructured":"Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: Servers for rigid and symmetric docking. Nucleic Acids Res. 2005;33:W363\u20137.","journal-title":"Nucleic Acids Res"},{"key":"434_CR28","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1172\/JCI34616","volume":"118","author":"A Silva","year":"2008","unstructured":"Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008;118:3762\u201374.","journal-title":"J Clin Invest"},{"key":"434_CR29","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood-2002-12-3861","volume":"103","author":"JT Barata","year":"2004","unstructured":"Barata JT, Boussiotis VA, Yunes JA, Ferrando, Moreau LA, Veiga JP, et al. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood. 2004;103:1891\u2013900.","journal-title":"Blood"},{"key":"434_CR30","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1182\/blood-2009-10-246876","volume":"115","author":"CM Henriques","year":"2010","unstructured":"Henriques CM, Rino J, Nibbs RJ, Graham GJ, Barata JT. IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7R\u03b1 in T cells. Blood. 2010;115:3269\u201377.","journal-title":"Blood"},{"key":"434_CR31","doi-asserted-by":"publisher","first-page":"31894","DOI":"10.1038\/srep31894","volume":"6","author":"NC Correia","year":"2016","unstructured":"Correia NC, Fragoso R, Carvalho T, Enguita FJ, Barata JT. MiR-146b negatively regulates migration and delays progression of T-cell acute lymphoblastic leukemia. Sci Rep. 2016;6:31894\u2013904.","journal-title":"Sci Rep"},{"key":"434_CR32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.str.2008.10.019","volume":"17","author":"CA McElroy","year":"2009","unstructured":"McElroy CA, Dohm JA, Walsh STR. Structural and biophysical studies of the human IL-7\/IL-7Ralpha complex. Structure. 2009;17:54\u201365.","journal-title":"Structure"},{"key":"434_CR33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/blood.V96.1.297","volume":"96","author":"L Karawajew","year":"2000","unstructured":"Karawajew L, Ruppert V, Wuchter C, K\u00f6sser A, Schrappe M, D\u00f6rken B, et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical\/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood. 2000;96:297\u2013306.","journal-title":"Blood"},{"key":"434_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"KL Bride","year":"2018","unstructured":"Bride KL, Vincent TL, Im S-Y, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131:995\u20139.","journal-title":"Blood"},{"key":"434_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nri1837","volume":"6","author":"PJ Carter","year":"2006","unstructured":"Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343\u201357.","journal-title":"Nat Rev Immunol"},{"key":"434_CR36","doi-asserted-by":"publisher","first-page":"22605","DOI":"10.18632\/oncotarget.25194","volume":"9","author":"E Senkevitch","year":"2018","unstructured":"Senkevitch E, Li W, Hixon JA, Andrews C, Cramer SD, Pauly GT, et al. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-R\u03b1 mutations. Oncotarget. 2018;9:22605\u201317.","journal-title":"Oncotarget"},{"key":"434_CR37","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1084\/jem.20110580","volume":"208","author":"C Shochat","year":"2011","unstructured":"Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie G, et al. Gain-of-function mutations in interleukin-7 receptor-\u03b1 (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 2011;208:901\u20138.","journal-title":"J Exp Med"},{"key":"434_CR38","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2015.141143","volume":"101","author":"A Mel\u00e3o","year":"2016","unstructured":"Mel\u00e3o A, Spit M, Cardoso BA, Barata JT. Optimal interleukin-7 receptor-mediated signaling, cell cycle progression and viability of t-cell acute lymphoblastic leukemia cells rely on casein kinase 2 activity. Haematologica. 2016;101:1368\u201379.","journal-title":"Haematologica"},{"key":"434_CR39","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, et al. Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125:1759\u201367.","journal-title":"Blood"},{"key":"434_CR40","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1038\/leu.2017.136","volume":"31","author":"C Delgado-Martin","year":"2017","unstructured":"Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, et al. JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017;31:2568\u201376.","journal-title":"Leukemia"},{"key":"434_CR41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1084\/jem.20122727","volume":"211","author":"LM Treanor","year":"2014","unstructured":"Treanor LM, Zhou S, Janke L, Churchman ML, Ma Z, Lu T, et al. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med. 2014;211:701\u201313.","journal-title":"J Exp Med"},{"key":"434_CR42","doi-asserted-by":"publisher","first-page":"G745","DOI":"10.1152\/ajpgi.00276.2004","volume":"288","author":"E Okada","year":"2005","unstructured":"Okada E, Yamazaki M, Tanabe M, Takeuchi T, Nanno M, Oshima S, et al. IL-7 exacerbates chronic colitis with expansion of memory IL-7Rhigh CD4\u2009+\u2009mucosal T cells in mice. Am J Physiol Gastrointest Liver Physiol. 2005;288:G745\u201354.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"434_CR43","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1002\/art.27578","volume":"62","author":"SAY Hartgring","year":"2010","unstructured":"Hartgring SAY, Willis CR, Alcorn D, Nelson LJ, Bijlsma JWJ, Lafeber FPJG, et al. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum. 2010;62:2716\u201325.","journal-title":"Arthritis Rheum"},{"key":"434_CR44","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1172\/JCI66287","volume":"124","author":"HLe Mai","year":"2014","unstructured":"Mai HLe, Boeffard F, Longis J, Danger R, Martinet B, Haspot F, et al. IL-7 receptor blockade following T cell depletion promotes long-term allograft survival. J Clin Invest. 2014;124:1723\u201333.","journal-title":"J Clin Invest"},{"key":"434_CR45","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clim.2015.08.007","volume":"161","author":"BR Lawson","year":"2015","unstructured":"Lawson BR, Gonzalez-Quintial R, Eleftheriadis T, Farrar MA, Miller SD, Sauer K, et al. Interleukin-7 is required for CD4\u2009+\u2009T cell activation and autoimmune neuroinflammation. Clin Immunol. 2015;161:260\u20139.","journal-title":"Clin Immunol"},{"key":"434_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-11255-4","volume":"7","author":"M Yasunaga","year":"2017","unstructured":"Yasunaga M, Manabe S, Matsumura Y. Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. Sci Rep. 2017;7:1\u201314.","journal-title":"Sci Rep"},{"key":"434_CR47","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/ard.2006.062547","volume":"66","author":"JAG Roon van","year":"2007","unstructured":"van Roon JAG, Hartgring SAY, Wenting-van Wijk M, Jacobs KMG, Tak P-P, Bijlsma JWJ, et al. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:664\u20139.","journal-title":"Ann Rheum Dis"},{"key":"434_CR48","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1002\/art.24754","volume":"60","author":"SAY Hartgring","year":"2009","unstructured":"Hartgring SAY, Van Roon JAG, Van WijkMW, Jacobs KMG, Jahangier ZN, Willis CR, et al. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis Rheum. 2009;60:2595\u2013605.","journal-title":"Arthritis Rheum"},{"key":"434_CR49","doi-asserted-by":"publisher","first-page":"e27528","DOI":"10.1371\/journal.pone.0027528","volume":"6","author":"R Gonzalez-Quintial","year":"2011","unstructured":"Gonzalez-Quintial R, Lawson BR, Scatizzi JC, Craft J, Kono DH, Baccala R, et al. Systemic autoimmunity and lymphoproliferation are associated with excess IL-7 and inhibited by IL-7R\u03b1 blockade. PLoS ONE. 2011;6:e27528\u2013540.","journal-title":"PLoS ONE"},{"key":"434_CR50","first-page":"93RA68","volume":"3","author":"LF Lee","year":"2011","unstructured":"Lee L-F, Axtell R, Tu GH, Logronio K, Dilley J, Yu J, et al. IL-7 promotes TH1 cell differentiation and its level in serum predicts response to interferon-\u03b2 in multiple sclerosis. Sci Transl Med. 2011;3:93RA68.","journal-title":"Sci Transl Med"},{"key":"434_CR51","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/ar3870","volume":"14","author":"SAY Hartgring","year":"2012","unstructured":"Hartgring SAY, Willis CR, Bijlsma JWJ, Lafeber FPJG, van Roon JAG. Interleukin-7-aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation. Arthritis Res Ther. 2012;14:R137.","journal-title":"Arthritis Res Ther"},{"key":"434_CR52","doi-asserted-by":"publisher","first-page":"12674","DOI":"10.1073\/pnas.1203795109","volume":"109","author":"LF Lee","year":"2012","unstructured":"Lee L-F, Logronio K, Tu GH, Zhai W, Ni I, Mei L, et al. Anti-IL-7 receptor- reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci. 2012;109:12674\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"434_CR53","doi-asserted-by":"publisher","first-page":"12668","DOI":"10.1073\/pnas.1203692109","volume":"109","author":"C Penaranda","year":"2012","unstructured":"Penaranda C, Kuswanto W, Hofmann J, Kenefeck R, Narendran P, Walker LSK, et al. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector\/memory T cells. Proc Natl Acad Sci. 2012;109:12668\u201373.","journal-title":"Proc Natl Acad Sci"},{"key":"434_CR54","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1002\/art.38007","volume":"65","author":"JO Jin","year":"2013","unstructured":"Jin JO, Kawai T, Cha S, Yu Q. Interleukin-7 enhances the Th1 response to promote the development of Sj\u00f6gren\u2019s syndrome-like autoimmune exocrinopathy in mice. Arthritis Rheum. 2013;65:2132\u201342.","journal-title":"Arthritis Rheum"},{"key":"434_CR55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11481-015-9629-6","volume":"11","author":"J Dunham","year":"2016","unstructured":"Dunham J, Lee LF, van Driel N, Laman JD, Ni I, Zhai W, et al. Blockade of CD127 exerts a dichotomous clinical effect in marmoset experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2016;11:73\u201383.","journal-title":"J Neuroimmune Pharmacol"},{"key":"434_CR56","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jbior.2018.09.012","volume":"71","author":"ML Oliveira","year":"2018","unstructured":"Oliveira ML, Akkapeddi P, Ribeiro D, Mel\u00e3o A, Barata JT. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: an update. Adv Biol Regul. 2018;71:88\u201396.","journal-title":"Adv Biol Regul"},{"key":"434_CR57","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ejca.2003.10.016","volume":"40","author":"MAA Al-Rawi","year":"2004","unstructured":"Al-Rawi MAA, Rmali K, Watkins G, Mansel RE, Jiang WG. Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. Eur J Cancer. 2004;40:494\u2013502.","journal-title":"Eur J Cancer"},{"key":"434_CR58","doi-asserted-by":"publisher","first-page":"e1414129","DOI":"10.1080\/2162402X.2017.1414129","volume":"7","author":"M Boesch","year":"2018","unstructured":"Boesch M, Onder L, Cheng HW, Novkovic M, M\u00f6rbe U, Sopper S, et al. Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness. Oncoimmunology. 2018;7:e1414129.","journal-title":"Oncoimmunology"},{"key":"434_CR59","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.2012.45.2052","volume":"31","author":"K Suzuki","year":"2013","unstructured":"Suzuki K, Kadota K, Sima CS, Nitadori JI, Rusch VW, Travis WD, et al. Clinical impact of immune microenvironment in stage i lung adenocarcinoma: Tumor interleukin-12 receptor \u03b22 (IL-12R b2), IL-7R, and stromal FoxP3\/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2013;31:490\u20138.","journal-title":"J Clin Oncol"},{"key":"434_CR60","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.cell.2015.02.011","volume":"160","author":"I Moraga","year":"2015","unstructured":"Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell. 2015;160:1196\u2013208.","journal-title":"Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0434-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:37:08Z","timestamp":1684618628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0434-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,8]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0434-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,8]]},"assertion":[{"value":"19 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}